The pharmaceutical industry has traditionally focused its communication efforts on its products. Even if its budget depends on the marketing area of the product and despite its major legal limits, the standard communication of pharmaceutical companies has been and is mainly centered on raising awareness about the diseases that these drugs seek to cure. Obviously, many corporate communication policies have also been developed with the media mainly those specialized in health and in some cases in general media or in media specializing in business management as well. This is evidenced by the great amount of journalistic awards promoted and/or sponsored by companies or CSR initiatives.

However, in spite of this communication effort, the pharmaceutical industry does not have a good reputation among society. Even if it is devoted to health and seeks to cure diseases and enhance people’s quality of life, it is seen in many cases as a sector with enormous profits at the expense of people’s health/illnesses, which does not get involved unless there are potential revenues, which does not support the people who need these treatments and have no financial resources or even does not support the society or the Administration that finances the treatments. In response, the pharmaceutical sector has endeavored to explain the research processes, the expenditures incurred and their need to recoup the investment, although without much success.

MORE INVESTIGATION

Nevertheless, we are now facing a paradigmatic change of scenario. The research has been “democratized”. The amount of studies and researches on new drugs for old and new diseases has skyrocketed. Technology has become cheaper and conducting new studies is increasingly easier.

This leads to two situations that might significantly affect the communication of pharmaceutical companies.

On the one hand, there are fewer and fewer unique products to treat diseases. The strict legislation on communication prohibits explicitly mentioning the product—especially if it is only sold with a doctor’s prescription—and thus, companies focus their efforts on the diseases for which they have the only or the best treatment. If we assume that there will be less and less diseases with just one treatment or, at least, with a medicine that clearly differs from the rest, communication efforts will have an increasingly smaller reward provided that they cannot mention the name of the medicine in question.

On the other hand, new medicines are only unique for a short period of time after being launched, since the constant innovation facilitates the rapid creation of new drugs for different diseases. The major efforts made to disseminate information on diseases and their treatments can thus be quickly ‘gobbled up’ by the new drugs which, moreover, reduce prices. Let us just remember the case of Sovaldi for Hepatitis C. A little over a year after its launch, new companies are announcing the launch of cheaper and equally efficient medicines.

BRAND CONSTRUCTION

However this situation has already taken place in other sectors in which products are also increasingly similar and it is difficult to note the differences, even with advertisements. The communication strategies which merely focus on the products are being replaced by brand building policies. The automotive sector, for instance, has started to create brand concepts around the central axis that defines the company and its cars. Associating brands to concepts such as sustainability and other concepts arising from it, has become a relevant element in almost all car brands. Special mention should also be made of the fact that, a few years ago, nobody knew the values behind a Procter & Gamble product and now we are thrilled by its viral videos supporting the mothers of athletes.
Here is where the corporate communication of the pharmaceutical industry starts to get stronger versus the communication of the product. Companies must necessarily identify which is their brand identity or what differentiates them from their competitors and also create an umbrella brand to protect and make their products more powerful and facilitate the launch of the new products beyond the disease and its curative action.

To that end, it will be necessary to implement innovative and different communication strategies with the aim of creating their own brand territory. Certain cases such as L’Oreal, which has focused its communication on women scientists or Coca-Cola in happiness and the brand experience are easily comparable to pharmaceutical communication.

Once our identity and our own brand territory are identified, a new communication strategy will have to be implemented, which shall foster and disseminate our position with all kinds of communication tools. From the most traditional ones, such as advocacy or the relation with the media to—and mainly—taking advantage of the new opportunities currently offered by communication, which require an innovative and digital transformation of the company and its communication activities. NetRelease (multimedia features with a strong emotional impact), Brand Journalism activities, Consumer Engagement or even gamification are some of the instruments that will enable us to establish ourselves in the desired territory.

The important thing is to know our space and be coherent, both in the messages and the communication instruments we will use to conquer it.

Focusing the core of the (corporate and product) communication in a concept that defines and differentiates us is the only way to explain our leadership beyond our products to the society and obtain the necessary “social license” (and much more in the health sector) to operate and, at the same time, grant an own identity and distinctive prestige to our products.

“The important thing is to know our space and be coherent, both in the messages and the communication instruments”
**María Cura** is a Partner and Managing director at LLORENTE & CUENCA Barcelona. She holds a Bachelor’s Degree in Law from the University of Barcelona. She worked as a commercial lawyer for four years and started her professional career in the field of communication in Gené & Asociados, a leading communication consultancy company in Barcelona. Subsequently, she joined USP Hospitales, where she was a partner and member of the Executive Committee for nine years, holding the position of Marketing and Communication Corporate Director. In 2009, she joined LLORENTE & CUENCA, where she provides advice to clients such as Panasonic, Nissan, Schneider Electric, DKV Seguros, Coca-Cola, L’Oréal, Singapore Airlines, CIRSA, Renta Corporación, Vida Caixa, Fundación MACBA, Fundación Dexeus, Roca & Junyent, among others. In 2014 she assisted the Government of Andorra in the banking crisis resulted from the intervention of BPA, as well as in the launch of UBER in Spain.

**Mònica Costa** Head of the Health Sector at LLORENTE & CUENCA Barcelona. Bachelor’s Degree in Information Science from the University of Navarra. She holds a postgraduate Degree in Public Relations from EADA. She has been Chief of Reports in Europa Press Catalonia, Head of Communication of the Consorci Hospitalaty of Catalonia and Corporate Communication Director in USP Hospitales. In addition to this, she taught communication in the Superior School of Marketing (Instituto Superior de Marketing) and in the International University of Catalonia. She has assisted clients such as Novartis, Novartis, Medichem, Palex Medical, Olympus, SARquavitae, Salud de la Mujer - Dexeus, Brill Pharma, Labco Quality Diagnostics, IMOncology and Plasmia Biotech, among others.

---

**Developing Ideas** by LLORENTE & CUENCA is a hub for ideas, analysis and trends. It is a product of the changing macroeconomic and social environment we live in, in which communication keeps moving forward at a fast pace.

**Developing Ideas** is a combination of global partnerships and knowledge exchange that identifies, defines and communicates new information paradigms from an independent perspective. **Developing Ideas** is a constant flow of ideas, foreseeing new times for information and management.

Because reality is neither black nor white, **Developing Ideas** exists.

[www.developing-ideas.com](http://www.developing-ideas.com)
[www.uno-magazine.com](http://www.uno-magazine.com)

**AMO** is the leading global network of strategic and financial communications consultancies, with over 940 professional consultants and offices in more than 20 countries.

The network brings together local market leaders with unrivalled knowledge of financial markets and cross-border transactions in the key financial centers of Europe, Asia and the Americas.

Providing sophisticated communications counsel for M&A and capital market transactions, media relations, investor relations and corporate crises, our member firms have established relationships with many S&P 500, FTSE 100, DAX 30, SMi, CAC 40 and IBEX 35 companies.

[www.amo-global.com](http://www.amo-global.com)